MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
about
New molecular targets in mantle cell lymphomaMDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.Nutlin-3 enhances sorafenib efficacy in renal cell carcinomaMDM2, MDMX and p53 in oncogenesis and cancer therapyGlobal effect of inauhzin on human p53-responsive transcriptomeTargeting p53 by small molecules in hematological malignancies.Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.Molecular targeted approaches in mantle cell lymphoma.HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphomaPharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.Targeting the p53 signaling pathway in cancer therapy - the promises, challenges and perils.Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases.The TP73 complex network: ready for clinical translation in cancer?Targeting p53-MDM2-MDMX loop for cancer therapy.Pharmacological activation of wild-type p53 in the therapy of leukemia.Regulation of cancer stem cells by RING finger ubiquitin ligases.Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.A stapled p53 helix overcomes HDMX-mediated suppression of p53.CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphomaTP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.PUMA protein in p53 regulatory molecule pattern determines the prognosis for patients with lymphoproliferative diseases.Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
P2860
Q26821766-390579F2-7EEA-43C2-98A9-A27145761925Q33915624-DF66115A-CBDB-41D5-A0B1-99D9A5CBDC88Q34127380-35586DC1-9864-4950-B309-0BC70C13E80DQ34166049-1F06216B-2630-44C4-8E73-BCD3CDAC3571Q34533232-981AB5CB-E7E7-401C-BE2F-8333BFAF0DD6Q34636996-8144C23A-A45B-449C-A527-76ED237BE4A7Q34963324-1B81009E-994E-48A5-8FC8-A8EC6825CA3EQ34982229-9DC222B9-3232-4752-8617-F4C95794DFBAQ35011473-A372D5D2-1434-4B16-922E-E2A2882CB8E3Q35071010-D6867EEA-E4FD-4EB4-B2B6-B937F82BEECFQ35127368-A4838760-BF3F-4753-80D2-D8EF5E341237Q35483623-F656D6AC-D940-492D-AFD0-0882F730B793Q35559055-5A77F05A-F988-4CEF-B765-33BB544125A6Q35795073-4BDAA125-E699-467B-A352-654ED0054465Q36312897-A764C2F1-C0FE-41E7-B30D-A7D477A6CC39Q36796813-1D672396-E3FC-4F1B-A011-FA343E8DFCE6Q38126476-DD92FAFC-C0B5-49DE-827D-C2CDB7A05C70Q38247168-A3C4E722-BFC1-48B7-BF4A-4E80EB6C8114Q38872029-47622034-F0CF-46B9-AAA2-424DE2439B68Q38881445-0BEEDA4A-93D1-400F-9C06-10D6B975E246Q39116877-D87DCB06-43A0-4D4F-ADF8-A15A958D4324Q39414811-0EFB8509-79C8-43C2-9A0F-CB882D82AF78Q39632109-48DAE920-84D2-48BF-8A7C-48403DA15C63Q39798807-43611D14-710E-491E-9152-FA0768E3E66CQ39801328-A95FA51C-76F2-471E-B7BA-D008CC6CAFFEQ39855621-37D4942B-EF2F-43E4-B813-F90B8D952A3EQ41583227-005F3301-1965-40BC-94B6-2652EFC057F8Q42070740-BA09448A-43C1-4ED1-9C7A-2F1B5ED13FD6Q44418379-1CB36E79-3FA5-45C8-AA59-B7B7788B53D9Q48864176-21FC4C0C-C894-405D-BDB9-33CA4EEB08E0Q50200634-B1068027-45AA-47FE-86B6-BAEDF9FEC5A9Q52777531-B4A73C04-3B51-4190-B93D-FF0F5176667F
P2860
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@en
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@nl
type
label
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@en
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@nl
prefLabel
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@en
MDM2 antagonist nutlin-3 displ ...... ivity in mantle cell lymphoma.
@nl
P2093
P1476
MDM2 antagonist nutlin-3 displ ...... tivity in mantle cell lymphoma
@en
P2093
Denise Sebasigari
Kazunori Miyake
Linhua Jin
Mark Raffeld
Martina Rudelius
Stefania Pittaluga
Theresa Davies-Hill
P304
P356
10.1158/1078-0432.CCR-08-0399
P407
P577
2009-02-01T00:00:00Z